La cadena de opciones muestra datos clave de las opciones de acciones de Actuate Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Actuate Therapeutics..

Actuate Therapeutics (NASDAQ:ACTU) Bolsa, Cadena de Opciones

Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics Inc

Barclays analyst Matthew Bouley maintains Champion Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) with a Equal-Weight and lowers the price target from $106 to $97.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Champion Homes, Lowers Price Target to $97

CORRECTION: Retail Stocks Are Lower

Argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">favorable safety profile</a>.
ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart&#8217;s bi-weekly and every <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44677982/argenx-highlights-vyvgart-data-at-aan-2025-setting-new-standard-in-sustained-efficacy-and-improved" rel="noreferrer noopener">three-week dosing schedules</a>.
<ul>
<li>Over the course of the study (126 weeks), 75% of patients showed sustained efficacy, achieving 2 points or more of improvement in MG activities of daily living (MG-ADL score) during more than 75% of study visits.</li>
<li>In addition, more than half (56.5%) of participants achieved minimal symptom expression (MSE) during the study.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42538247/analysts-optimistic-on-biohavens-bhv-1300-ahead-of-2025-catalysts" rel="noreferrer noopener">Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval</a>
Interim results of ADAPT-SC+ demonstrate consistent and repeatable improvements in MG-ADL (functional score) and MG Quality of Life (MG-QoL) scores in gMG patients treated with Vyvgart Hytrulo.
There was no observed increase in infections or injection-site reactions over nine treatment cycles. Also, the proportion of patients achieving MSE was consistent across multiple cycles.
ADHERE+ data demonstrated Vyvgart Hytrulo delivers long-term clinical efficacy.
The study showed functional improvements across aINCAT disability scores (&gt;1-point), grip strength (&gt;17 kPa), and the I-RODS scale (&gt;8 points) at week 36 compared to baseline at entry to the standard of care withdrawal phase.
In addition, the majority of ADHERE patients who relapsed during randomized treatment withdrawal stage, restabilized on Vyvgart – 50% as early as week 4.
Argenx is pursuing label extension for Vyvgart, including through two Phase 3 studies for seronegative gMG (ADAPT-SERON) and ocular MG (ADAPT-OCULUS).
Price Action: ARGX stock is up 3.05% at $566.76 at the last check on Tuesday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44694920/trump-administration-reverses-bidens-plan-for-medicare-coverage-of-obesity-drugs-like-ozempic-and-zepbound" target="_blank" rel="noreferrer noopener">Trump Administration Reverses Biden&#8217;s Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

ARGX

Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

ANF, COLM, CPRI, GAP, GES, HBI, HELE, LULU, PVH, UA, UAA, W, XRT

WIIM

COLM

CPRI

HELE

LULU

Shares of retail and apparel stocks are trading lower as investors weigh the potential impacts of tariffs on the sector. Economic uncertainty could also cloud consumer spending outlook.

Whales with a lot of money to spend have taken a noticeably bullish stance on Palantir Technologies.
Looking at options history for Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) we detected 31 trades.
If we consider the specifics of each trade, it is accurate to state that 48% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $347,038 and 24, calls, for a total amount of $1,846,334.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $150.0 for Palantir Technologies over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Palantir Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palantir Technologies's whale activity within a strike price range from $55.0 to $150.0 in the last 30 days. 
<h3>Palantir Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744136225_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$21.5</td>
<td>$21.3</td>
<td>$21.5</td>
<td>$115.00</td>
<td>$632.1K</td>
<td>1.2K</td>
<td>863</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$4.1</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$84.00</td>
<td>$199.3K</td>
<td>2.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$19.25</td>
<td>$18.8</td>
<td>$19.05</td>
<td>$100.00</td>
<td>$112.6K</td>
<td>3.6K</td>
<td>462</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$8.05</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$90.00</td>
<td>$84.0K</td>
<td>14.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$6.5</td>
<td>$6.3</td>
<td>$6.42</td>
<td>$80.00</td>
<td>$69.0K</td>
<td>4.7K</td>
<td>301</td>
</tr>
</tbody>
</table>

<h3>About Palantir Technologies</h3>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
Having examined the options trading patterns of Palantir Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Palantir Technologies Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 97,926,469, with PLTR's price up by 3.24%, positioned at $80.36.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Expert Opinions on Palantir Technologies</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $125.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Buy rating for Palantir Technologies, targeting a price of $125. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Palantir Technologies with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

PLTR

Smart Money Is Betting Big In PLTR Options

Whales with a lot of money to spend have taken a noticeably bearish stance on Alibaba Gr Hldgs.
Looking at options history for Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) we detected 37 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 45% with bearish.
From the overall spotted trades, 21 are puts, for a total amount of $2,313,864 and 16, calls, for a total amount of $1,326,013.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $82.5 to $200.0 for Alibaba Gr Hldgs over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Alibaba Gr Hldgs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alibaba Gr Hldgs's whale trades within a strike price range from $82.5 to $200.0 in the last 30 days. 
<h3>Alibaba Gr Hldgs Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744136219_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$10.45</td>
<td>$9.9</td>
<td>$10.1</td>
<td>$105.00</td>
<td>$353.5K</td>
<td>3.0K</td>
<td align="right">600</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.15</td>
<td>$10.9</td>
<td>$11.0</td>
<td>$105.00</td>
<td>$330.0K</td>
<td>20.2K</td>
<td align="right">480</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.7</td>
<td>$10.15</td>
<td>$10.3</td>
<td>$100.00</td>
<td>$309.0K</td>
<td>5.4K</td>
<td align="right">0</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.55</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$82.50</td>
<td>$252.7K</td>
<td>95</td>
<td align="right">245</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$25.5</td>
<td>$24.5</td>
<td>$24.9</td>
<td>$110.00</td>
<td>$249.0K</td>
<td>2.6K</td>
<td align="right">600</td>
</tr>
</tbody>
</table>

<h3>About Alibaba Gr Hldgs</h3>
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.
<h3>Alibaba Gr Hldgs's Current Market Status</h3>
<ul>
<li>Trading volume stands at 35,174,347, with BABA's price down by -5.65%, positioned at $99.99.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Expert Opinions on Alibaba Gr Hldgs</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $170.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Alibaba Gr Hldgs, targeting a price of $170. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Alibaba Gr Hldgs options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

BABA

A Closer Look at Alibaba Gr Hldgs's Options Market Dynamics

Investors with a lot of money to spend have taken a bearish stance on Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SMCI, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Super Micro Computer.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 53%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $360,476, and 10 are calls, for a total amount of $562,458.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $50.0 for Super Micro Computer, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Super Micro Computer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Super Micro Computer's whale trades within a strike price range from $3.0 to $50.0 in the last 30 days. 
<h3>Super Micro Computer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744136214_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$8.2</td>
<td>$8.0</td>
<td>$8.2</td>
<td>$40.00</td>
<td>$162.3K</td>
<td>2.8K</td>
<td align="right">203</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$7.3</td>
<td>$7.15</td>
<td>$7.3</td>
<td>$35.00</td>
<td>$116.8K</td>
<td>1.9K</td>
<td align="right">22</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.75</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$35.00</td>
<td>$88.6K</td>
<td>3.5K</td>
<td align="right">101</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$33.55</td>
<td>$31.45</td>
<td>$32.32</td>
<td>$3.00</td>
<td>$77.5K</td>
<td>292</td>
<td align="right">0</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.85</td>
<td>$12.75</td>
<td>$12.85</td>
<td>$45.00</td>
<td>$57.8K</td>
<td>4.7K</td>
<td align="right">81</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, Big Data, high-performance computing, and the "Internet of Things" embedded markets. Its solutions include server, storage, blade, and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular, and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
<h3>Present Market Standing of Super Micro Computer</h3>
<ul>
<li>With a volume of 43,719,762, the price of SMCI is up 0.88% at $33.29. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What Analysts Are Saying About Super Micro Computer</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $52.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Rosenblatt has revised its rating downward to Buy, adjusting the price target to $60. 
&#x2A; In a positive move, an analyst from JP Morgan has upgraded their rating to Neutral and adjusted the price target to $45. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Super Micro Computer with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

SMCI

Check Out What Whales Are Doing With SMCI

On Friday, China&#8217;s finance ministry announced a 34%&nbsp;tariff on all goods imported&nbsp;from the U.S., effective April 10, in response to the U.S. administration&#8217;s 54% duties imposed by the Trump-led administration during the so-called <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">Liberation Day last week</a>.
Trump has&nbsp;threatened to impose an additional 50% duty&nbsp;on Chinese imports if Beijing does not <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44679330/will-trump-impose-higher-tariffs-on-china-crypto-bettors-now-see-an-80-possibility" rel="noreferrer noopener">drop the 34% tariffs</a>.
On Monday, Trump hinted at more openness in trade negotiations with China after threatening to impose a 50% tariff on top of the 54% already levied.
&#8220;China also wants to make a deal badly, but they don&#8217;t know how to get it started,&#8221; <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/04/44686417/wall-street-soars-as-trump-teases-trade-deals-magnificent-seven-add-over-500-billion-in-market-value" rel="noreferrer noopener">Trump wrote</a>.
Wedbush analyst Daniel Ives writes that &#8220;saying we can just make this in the USA&#8221; understates how complex the supply chain in Asia really is—and how electronics, chips, semiconductors, hardware, and smartphones have been built for U.S. consumers over the past 30 years.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/04/44686417/wall-street-soars-as-trump-teases-trade-deals-magnificent-seven-add-over-500-billion-in-market-value" rel="noreferrer noopener">Wall Street Soars As Trump Teases Trade Deals, Magnificent 7 Add Over $500 Billion In Market Value</a>
&#8220;The reason I believe this is the biggest debacle ever seen in the markets is because its purely self-inflicted by Trump, and the logic about &#8220;near-term pain&#8221; is being way miscalculated, which speaks to our concern. It&#8217;s very easy to say &#8220;build in America&#8221; behind a microphone in the Beltway&#8230;the reality is so much different it&#8217;s almost a scary concept,&#8221; says Daniel Ives.
For U.S. tech/auto companies, tariffs are like flipping a boat with no life rafts.
The list of vulnerable companies is long and includes Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), and Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), among others.
Building a factory in the U.S. takes four to five years. The analyst explains that high labor costs and other expenses in the U.S. don&#8217;t align with how modern supply chains are designed to operate. This makes it hard to compete with Chinese tech giants like BYD Co Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), Huawei, Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Tencent Holdings Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCTZF#OTC">TCTZF</a>)—and many others—a big opportunity to expand their global reach.
Also, much of the key technology and intellectual property behind these supply chains is already deeply rooted in Asia. So, any effort to shift production to the U.S. would take at least a decade to make a real impact, Wedbush analyst writes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44696126/trump-administration-shuts-down-the-department-of-justices-crypto-crime-unit" target="_blank" rel="noreferrer noopener">Trump Administration Shuts Down The Department Of Justice&#8217;s Crypto Crime Unit</a></li>
</ul>
 Image: Shutterstock

Analyst Color

AAPL

BYDDF

BYDDY

MSFT

NVDA

TCEHY

TCTZF

Trump Tariff Strategy Creates 'Self-Inflicted Market Debacle': Analyst

Macro Notification

Politics

Global

State Dept: Russian And U.S. Delegations Will Meet In Istanbul For A Second Time On April 10-Reuters

In a <a href="https://www.benzinga.com/topic/cryptocurrencies">crypto-linked</a> stock market that oscillates like a pendulum, Bitwise Asset Management introduced a plan to translate that volatility into money. The company has introduced <a href="https://www.benzinga.com/etfs">three new ETFs</a>, each targeting option income strategies based on some of the most volatile stocks in the crypto universe: Bitwise MSTR Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMST#NYSE">IMST</a>), Bitwise COIN Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICOI#NYSE">ICOI</a>) and the Bitwise MARA Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMRA#NYSE">IMRA</a>).
Each of these funds is structured on a covered call strategy intended to capture income by selling options on individual shares of MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), and MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>). The concept? Ride the turbulence in the market on your side. Receive premiums on selling options and maintain a long position to derive at least a partial benefit from any upside the stock yields.
Also Read: <a href="https://www.benzinga.com/real-estate/reit/25/04/44683691/lpre-etf-looks-past-reits-to-capture-greater-real-estate-economy">LPRE ETF Looks Past REITs To Capture &#8216;Greater&#8217; Real Estate Economy (CORRECTED)</a>
These are not passive, rules-based products. Rather, they&#8217;re operated with a hands-on mindset by Bitwise&#8217;s Head of Alpha Strategies, Jeff Park. &#8220;It's essential to be constantly monitoring news, capital flows, regulatory developments, options pricing, market sentiment, and other dynamics to most intelligently capitalize on this strategy. That's the approach we're taking with IMST, ICOI, and IMRA, and we hope to bring investors the combination of monthly income and strong, limited participation in equity gains as a result,&#8221; he said.
Park is accompanied by a group of co-managers—Jennifer Thornton, Daniela Padilla, and Gayatri Choudhury—who will guide these funds with daily active management, which is fairly uncommon in the ETF space.
The <a href="https://www.businesswire.com/news/home/20250403628192/en/Bitwise-Launches-Option-Income-ETF-Suite-a-Dynamic-Active-Approach-to-Covered-Calls-on-MSTR-COIN-and-MARA">objective </a>is clear: earn monthly returns for investors while sharing in some of the capital gain in these stocks. There&#8217;s a trade-off, naturally—selling calls limits the upside potential, but the ongoing premiums provide a predictable income stream, which is particularly attractive in volatile markets.
Bitwise CEO Hunter Horsley says crypto's volatility isn't just something to endure—it's something to harness.
Interestingly, these funds don&#8217;t actually own shares of MSTR, COIN or MARA. Rather, they employ synthetic exposure to mimic the stock positions. Pure equity players may want to look elsewhere, but for those who wish to combine crypto market themes with an income strategy, this launch may be the sweet spot.
Each fund has a 0.98% net expense fee, although IMST and ICOI are associated with a minor fee waiver that cuts the gross fee from 0.99% until March 2027.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44695765/crypto-etfs-sink-as-trump-tariffs-trigger-panic-this-could-reset-the-macro-narrative">Trump Tariffs Spark $800M Crypto ETF Rout: Can The Macro Narrative Shift?</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

COIN

Bitwise Funds Trust Bitwise COIN Option Income Strategy ETF

ICOI

IMRA

IMST

MARA

MSTR

Bitwise Turns Crypto Volatility Into Yield With New ETF Trio

Hedge fund manager Dan Loeb had five major financial stocks in the Third Point LLC portfolio, <a href="https://www.benzinga.com/topic/third-point-llc">each on the downtrend</a>. 
What Happened: Last week, shares of companies within the broader financials sector traded lower as markets reacted to President Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44678625/did-trump-team-manipulate-tariff-formula-to-achieve-higher-rates-experts-weigh-in-as-they-think-whole-thing-was-rigged" target="_blank" rel="noreferrer noopener">sweeping tariff announcement</a>.
Here&#8217;s a look at some of Loeb&#8217;s financial stocks year-to-date:
<ul>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>): Shares dropped 33.54% compared to Fidelity Disruptive Finance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>) decline of 17.85% YTD. As of the fourth quarter <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" target="_blank" rel="noreferrer noopener">of </a>2024, the investor lowered the stake to 400,000 shares from 950,000 shares as of the third quarter <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml" target="_blank" rel="noreferrer noopener">of </a>2024.</li>
</ul>
<ul>
<li>Brookfield Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>): The stock dipped 20.59% vs its peer BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) that plummetted 19.92% YTD. Loeb raised the stake to 4,990,000 shares as of the fourth quarter of 2024 from 4,725,000 as of the third quarter of 2024.</li>
</ul>
<ul>
<li>Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): Shares were down 14.28% compared to Davis Fundamental ETF Trust Davis Select Financial ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DFNL#BATS">DFNL</a>), which saw a decrease of 9.68% YTD. Third Point acquired 925,000 shares in the fourth quarter of 2024.</li>
</ul>
<ul>
<li>LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>): The company&#8217;s shares tumbled 13.58% versus Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GABF#NYSE">GABF</a>) decrease of 15.99% YTD. The investor increased their stake to 655,000 shares in the fourth quarter of 2024 from 485,000 shares as of the third quarter of 2024.</li>
</ul>
<ul>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>): The stock dived 14.30% compared to iShares Focused Value Factor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOVL#NYSE">FOVL</a>) decline of 12.16% YTD. Loeb acquired 640,000 shares in the company in the fourth quarter of 2024.</li>
</ul>
Why It Matters: U.S. banks and economists are now on recession watch.
JPMorgan analyst Maia G. Crook raised the U.S. recession risk to 60% from 40% last month, citing tariff hikes as the biggest U.S. tax<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy" target="_blank" rel="noreferrer noopener"> increase in decades</a>.
Last week, Trump argued it was necessary to address the U.S.'s <a href="https://www.benzinga.com/general/market-summary/25/04/44623604/us-stock-likely-to-open-lower-following-trumps-tariffs-worse-than-the-worst-case-scenario-says-analyst" target="_blank" rel="noreferrer noopener">&#8220;large and persistent trade deficit</a>,&#8221; adding: &#8220;Treat us like we treat you.&#8221;
The Trump administration proposed steep new tariffs on several countries, including 54% on China, 46% on Vietnam, 36% on Thailand, and 20% on the EU, while maintaining current rates for USMCA-<a href="https://www.benzinga.com/25/04/44589523/trumps-liberation-day-tariff-plan-could-ignite-global-trade-shakeup-betting-markets-price-in-the-pain" target="_blank" rel="noreferrer noopener">compliant goods from Mexico and Canada</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44496640/these-5-dan-loeb-portfolio-stocks-are-up-over-30-in-the-past-year" target="_blank" rel="noreferrer noopener">These 5 Dan Loeb Portfolio Stocks Are Up Over 30% In The Past Year</a></li>
</ul>
Image: Shutterstock

Mid Cap

DFNL

FDFF

FOVL

Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF

GABF

LPLA

Tariffs Test Loeb's Financial Picks: Third Point Adjusts Bets As Markets Brace For Economic Blowback

Barclays analyst Matthew Bouley maintains Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) with a Overweight and lowers the price target from $149 to $130.

Barclays Maintains Overweight on Advanced Drainage Systems, Lowers Price Target to $130

CORRECTION: B of A Securities analyst Dimple Gosai maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and lowers the price target from $236 to $215, analyst name updated.

FSLR

CORRECTION: B of A Securities Maintains Buy on First Solar, Lowers Price Target to $215 (Analyst Name Updated)

7 analysts have shared their evaluations of Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.1, a high estimate of $30.00, and a low estimate of $5.73. Highlighting a 13.28% decrease, the current average has fallen from the previous average price target of $24.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1744135258_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Voyager Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $30.00&#x7C;$30.00 &#x7C; 
&#x7C;Sumant Kulkarni &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $12.00&#x7C;$14.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $30.00&#x7C;$30.00 &#x7C; 
&#x7C;Yanan Zhu &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $10.00&#x7C;$12.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $30.00&#x7C;$30.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $30.00&#x7C;$30.00 &#x7C; 
&#x7C;Pete Stavropoulos &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Overweight &#x7C; $5.73&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Voyager Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Voyager Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Voyager Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Voyager Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VYGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Voyager Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Voyager Therapeutics</h2>
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
<h3>Understanding the Numbers: Voyager Therapeutics's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Voyager Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -93.03%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Voyager Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -549.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Voyager Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -10.95%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.42%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Voyager Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.15.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VYGR

7 Analysts Assess Voyager Therapeutics: What You Need To Know

Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) has been analyzed by 21 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $199.1, a high estimate of $236.00, and a low estimate of $143.00. This current average reflects an increase of 4.42% from the previous average price target of $190.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1744135249_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Expedia Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Doug Anmuth &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $170.00&#x7C;$205.00 &#x7C; 
&#x7C;Ken Gawrelski &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $143.00&#x7C;$199.00 &#x7C; 
&#x7C;Jed Kelly &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $230.00&#x7C;$235.00 &#x7C; 
&#x7C;Greg Miller &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $175.00&#x7C;$163.00 &#x7C; 
&#x7C;Ronald Josey &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $217.00&#x7C;$200.00 &#x7C; 
&#x7C;Shyam Patil &#x7C;Susquehanna &#x7C;Raises &#x7C;Neutral &#x7C; $205.00&#x7C;$190.00 &#x7C; 
&#x7C;Brian Pitz &#x7C;BMO Capital &#x7C;Raises &#x7C;Market Perform &#x7C; $190.00&#x7C;$165.00 &#x7C; 
&#x7C;Trevor Young &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $187.00&#x7C;$166.00 &#x7C; 
&#x7C;Deepak Mathivanan &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $210.00&#x7C;$180.00 &#x7C; 
&#x7C;Jed Kelly &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $235.00&#x7C;$210.00 &#x7C; 
&#x7C;Naved Khan &#x7C;B. Riley Securities &#x7C;Raises &#x7C;Buy &#x7C; $235.00&#x7C;$220.00 &#x7C; 
&#x7C;Daniel Kurnos &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $225.00&#x7C;$200.00 &#x7C; 
&#x7C;Ken Gawrelski &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $199.00&#x7C;$168.00 &#x7C; 
&#x7C;Tom White &#x7C;DA Davidson &#x7C;Raises &#x7C;Neutral &#x7C; $205.00&#x7C;$190.00 &#x7C; 
&#x7C;Daniel Kurnos &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $200.00&#x7C;$200.00 &#x7C; 
&#x7C;Deepak Mathivanan &#x7C;Cantor Fitzgerald &#x7C;Lowers &#x7C;Neutral &#x7C; $180.00&#x7C;$190.00 &#x7C; 
&#x7C;Ken Gawrelski &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $168.00&#x7C;$172.00 &#x7C; 
&#x7C;Brian Nowak &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $185.00&#x7C;$180.00 &#x7C; 
&#x7C;Trevor Young &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $166.00&#x7C;$153.00 &#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $236.00&#x7C;$208.00 &#x7C; 
&#x7C;John Staszak &#x7C;Argus Research &#x7C;Raises &#x7C;Buy &#x7C; $220.00&#x7C;$210.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Expedia Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Expedia Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Expedia Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXPE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Expedia Group analyst ratings.</a>
<h2>Discovering Expedia Group: A Closer Look</h2>
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
<h3>Key Indicators: Expedia Group's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Expedia Group showcased positive performance, achieving a revenue growth rate of 10.29% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Expedia Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.39% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Expedia Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 20.77%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Expedia Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.31% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Expedia Group's debt-to-equity ratio surpasses industry norms, standing at 4.19. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPE

Assessing Expedia Group: Insights From 21 Financial Analysts

Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $20.62, a high estimate of $22.00, and a low estimate of $20.00. Experiencing a 2.69% decline, the current average is now lower than the previous average price target of $21.19. 
<img src="https://www.benzinga.com/files/images/story/2025/1744135239_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Hercules Capital is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Johnson &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Outperform &#x7C; $20.50&#x7C;$21.50 &#x7C; 
&#x7C;Crispin Love &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $20.00&#x7C;$23.00 &#x7C; 
&#x7C;Casey Alexander &#x7C;Compass Point &#x7C;Raises &#x7C;Neutral &#x7C; $20.00&#x7C;$18.25 &#x7C; 
&#x7C;Brian McKenna &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $22.00&#x7C;$22.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hercules Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hercules Capital compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Hercules Capital's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Hercules Capital's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HTGC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hercules Capital analyst ratings.</a>
<h2>About Hercules Capital</h2>
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
<h3>Hercules Capital: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Hercules Capital's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -40.98%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Hercules Capital's net margin excels beyond industry benchmarks, reaching 74.7%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hercules Capital's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Hercules Capital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.64%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Hercules Capital's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.9.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HTGC

What Analysts Are Saying About Hercules Capital Stock

In the last three months, 6 analysts have published ratings on Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.67, a high estimate of $25.00, and a low estimate of $9.00. Experiencing a 31.51% decline, the current average is now lower than the previous average price target of $21.42. 
<img src="https://www.benzinga.com/files/images/story/2025/1744135228_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Webtoon Entertainment by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Doug Anmuth &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $9.00&#x7C;$10.00 &#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $15.00&#x7C;$25.00 &#x7C; 
&#x7C;Doug Anmuth &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $10.00&#x7C;$12.00 &#x7C; 
&#x7C;Matthew Cost &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $25.00&#x7C;$48.00 &#x7C; 
&#x7C;Matthew Cost &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $16.00&#x7C;$17.50 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Webtoon Entertainment. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Webtoon Entertainment compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Webtoon Entertainment's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Webtoon Entertainment's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WBTN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Webtoon Entertainment analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Webtoon Entertainment Better</h2>
Webtoon Entertainment Inc is a storytelling platform where a vibrant community of creators and users discover, create and share new content. It has pioneered a cultural movement by revolutionizing the storytelling format and democratizing content creation and publication connecting 24 million creators with approximately 170 million monthly active users in over 150 countries around the world.
<h3>Webtoon Entertainment: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Webtoon Entertainment's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.62% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Webtoon Entertainment's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -26.35%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Webtoon Entertainment's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.02%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Webtoon Entertainment's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.58%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Webtoon Entertainment's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WBTN

Forecasting The Future: 6 Analyst Projections For Webtoon Entertainment

Citigroup's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) short percent of float has risen 11.6% since its last report. The company recently reported that it has 37.99 million shares sold short, which is 2.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Citigroup Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744135226_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Citigroup has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Citigroup's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Citigroup's peer group average for short interest as a percentage of float is 1.19%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Citigroup's Recent Short Interest

In the current market session, United States Steel Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) stock price is at $44.27, after a 0.53% decrease. However, over the past month, the company's stock increased by 19.44%, and in the past year, by 3.88%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744135223_0.png" alt="Past Year Chart" />

<h3>Comparing United States Steel P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
United States Steel has a lower P/E than the aggregate P/E of 38.42 of the Metals &amp; Mining industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744135223_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: United States Steel

Pinnacle West Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) short percent of float has risen 8.36% since its last report. The company recently reported that it has 3.80 million shares sold short, which is 3.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Pinnacle West Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744135222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pinnacle West Capital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pinnacle West Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Pinnacle West Capital's peer group average for short interest as a percentage of float is 2.22%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Pinnacle West Capital?

Press Releases

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate Therapeutics to be Added to Russell 2000® Index

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Comments

Actuate Therapeutics

Actuate Therapeutics (ACTU) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL